Women's Health

Longer sitting bout duration conferred worse parameters of CVD risk in women, but the effect on blood sugar/glucose was most pronounced in Hispanic women, according to a study published in a Go Red for Women-focused issue of the Journal of the American Heart Association.

The FDA recently approved Twirla, a weekly contraceptive patch containing 30 mcg ethinyl estradiol and 120 mcg levonorgestrel, for women of reproductive age with a BMI less than 30 kg/m2 and for whom a combined hormonal contraceptive is appropriate, its manufacturer announced in a press release.

On Friday, Feb. 7, the Healio team wears red in support of the American Heart Association’s National Wear Red Day campaign to increase awareness of heart disease in women.

Compared with men, women admitted to the ED with syncope had lower mortality, regardless of discharge status, and were less likely to be admitted to the hospital, according to findings published in JACC: Clinical Electrophysiology.

Higher magnesium intake was linked to a statistically significant risk reduction in fatal coronary heart disease and a risk reduction for sudden cardiac death among postmenopausal women, according to an analysis published in the Journal of Women’s Health.

Although binge drinking has increased among mothers in the United States from 2006 to 2018, the increase was greater among women without children, according to a study published in PLoS Medicine.

Physically active adults, particularly women, have lower risk for atrial fibrillation and ventricular arrhythmia compared with inactive adults, according to research published in the European Heart Journal.

BP elevations occurred more rapidly in women compared with men and as early as the third decade of life, which may explain why CVD presents at different times between both sexes, according to a study published in JAMA Cardiology.

Women who were enrolled in clinical trials had a lower risk for major adverse CV events compared with men after non-ST segment elevation ACS, according to a sex-specific analysis published in the Journal of the American College of Cardiology.

PHILADELPHIA — Sacubitril/valsartan reduced the risk for HF hospitalization more in women compared with men, and the overall benefit of sacubitril/valsartan was driven by a benefit in patients with chronic HF and a left ventricular ejection fraction below the normal range, according to two analyses of the PARAGON-HF trial of patients with HF with preserved EF presented at the American Heart Association Scientific Sessions.